AAPL   366.74 (+0.72%)
FB   236.32 (-0.52%)
GOOGL   1,457.69 (+1.09%)
NVDA   387.75 (+1.72%)
CGC   16.45 (-0.12%)
BABA   221.48 (+2.56%)
MU   50.17 (+0.95%)
GE   6.93 (+2.67%)
TSLA   1,204.80 (+7.61%)
AMD   52.55 (-0.06%)
T   30.22 (+1.04%)
ACB   12.09 (-1.47%)
DIS   113.26 (+0.21%)
BA   182.92 (+1.44%)
AAPL   366.74 (+0.72%)
FB   236.32 (-0.52%)
GOOGL   1,457.69 (+1.09%)
NVDA   387.75 (+1.72%)
CGC   16.45 (-0.12%)
BABA   221.48 (+2.56%)
MU   50.17 (+0.95%)
GE   6.93 (+2.67%)
TSLA   1,204.80 (+7.61%)
AMD   52.55 (-0.06%)
T   30.22 (+1.04%)
ACB   12.09 (-1.47%)
DIS   113.26 (+0.21%)
BA   182.92 (+1.44%)
AAPL   366.74 (+0.72%)
FB   236.32 (-0.52%)
GOOGL   1,457.69 (+1.09%)
NVDA   387.75 (+1.72%)
CGC   16.45 (-0.12%)
BABA   221.48 (+2.56%)
MU   50.17 (+0.95%)
GE   6.93 (+2.67%)
TSLA   1,204.80 (+7.61%)
AMD   52.55 (-0.06%)
T   30.22 (+1.04%)
ACB   12.09 (-1.47%)
DIS   113.26 (+0.21%)
BA   182.92 (+1.44%)
AAPL   366.74 (+0.72%)
FB   236.32 (-0.52%)
GOOGL   1,457.69 (+1.09%)
NVDA   387.75 (+1.72%)
CGC   16.45 (-0.12%)
BABA   221.48 (+2.56%)
MU   50.17 (+0.95%)
GE   6.93 (+2.67%)
TSLA   1,204.80 (+7.61%)
AMD   52.55 (-0.06%)
T   30.22 (+1.04%)
ACB   12.09 (-1.47%)
DIS   113.26 (+0.21%)
BA   182.92 (+1.44%)
Log in

NASDAQ:PRNBPrincipia Biopharma Stock Price, Forecast & News

$58.38
-1.41 (-2.36 %)
(As of 07/2/2020 09:57 AM ET)
Add
Compare
Today's Range
$58.17
Now: $58.38
$61.16
50-Day Range
$56.28
MA: $62.06
$67.88
52-Week Range
$25.35
Now: $58.38
$75.65
Volume361,673 shs
Average Volume486,729 shs
Market Capitalization$1.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.61
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Read More
Principia Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRNB
CUSIPN/A
CIKN/A
Phone650-416-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.16 million
Book Value$10.95 per share

Profitability

Net Income$-53,790,000.00

Miscellaneous

Employees65
Market Cap$1.93 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive PRNB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter.

Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions

How has Principia Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRNB stock has increased by 8.3% and is now trading at $58.38. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Principia Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Principia Biopharma.

When is Principia Biopharma's next earnings date?

Principia Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Principia Biopharma.

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc (NASDAQ:PRNB) issued its earnings results on Wednesday, May, 6th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.20. View Principia Biopharma's earnings history.

What price target have analysts set for PRNB?

5 analysts have issued 12-month target prices for Principia Biopharma's stock. Their forecasts range from $76.00 to $82.00. On average, they expect Principia Biopharma's stock price to reach $78.60 in the next year. This suggests a possible upside of 34.6% from the stock's current price. View analysts' price targets for Principia Biopharma.

Has Principia Biopharma been receiving favorable news coverage?

Media headlines about PRNB stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Principia Biopharma earned a news impact score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Principia Biopharma.

Who are some of Principia Biopharma's key competitors?

What other stocks do shareholders of Principia Biopharma own?

Who are Principia Biopharma's key executives?

Principia Biopharma's management team includes the following people:
  • Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)
  • Mr. Martin Babler, CEO & Director (Age 54)
  • Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)
  • Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)
  • Dr. David M. Goldstein, Chief Scientific Officer (Age 53)

When did Principia Biopharma IPO?

(PRNB) raised $75 million in an IPO on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Principia Biopharma's stock symbol?

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

How do I buy shares of Principia Biopharma?

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Principia Biopharma's stock price today?

One share of PRNB stock can currently be purchased for approximately $58.38.

How big of a company is Principia Biopharma?

Principia Biopharma has a market capitalization of $1.93 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.

What is Principia Biopharma's official website?

The official website for Principia Biopharma is www.principiabio.com.

How can I contact Principia Biopharma?

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.